Ireland - English - HPRA (Health Products Regulatory Authority)

chemo iberica s.l. - telmisartan; hydrochlorothiazide - tablet - 80 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; telmisartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

chemo iberica s.l. - telmisartan; hydrochlorothiazide - tablet - 80 mg/25 milligram(s) - angiotensin ii antagonists and diuretics; telmisartan and diuretics

Ireland - English - HPRA (Health Products Regulatory Authority)

chemo iberica s.l. - telmisartan; hydrochlorothiazide - tablet - 40 mg/12.5 milligram(s) - angiotensin ii antagonists and diuretics; telmisartan and diuretics

Israel - English - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 200 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 1000 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer.gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - panax ginseng,tribulus terrestris,zinc gluconate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sini australia pty ltd - zinc gluconate, quantity: 41.66 mg (equivalent: zinc, qty 5 mg); hydrolysed collagen, quantity: 400 mg; bambusa breviflora, quantity: 32 mg (equivalent: bambusa breviflora, qty 320 mg); biotin, quantity: 2.5 mg - capsule, hard - excipient ingredients: colloidal anhydrous silica; magnesium stearate; ascorbic acid; hypromellose; purified water; carrageenan; glycerol - maintain/support hair growth ; enhance/improve/promote/increase hair strength/thickness ; decrease/reduce hair loss/thinning ; decrease/reduce/relieve skin dryness ; helps reduce occurrence of skin dryness ; maintain/support skin health ; helps enhance/improve skin internal structure ; maintain/support skin elasticity ; helps protect skin elastin from breaking down ; maintain/support skin integrity/structure ; helps enhance/promote skin regeneration ; helps enhance/improve skin strength ; enhance/improve/promote skin repair/healing ; maintain/support skin repair/healing/regeneration

Canada - English - Health Canada

biomed pharma - ondansetron (ondansetron hydrochloride) - tablet - 4mg - ondansetron (ondansetron hydrochloride) 4mg - 5-ht3 receptor antagonists

Canada - English - Health Canada

biomed pharma - ondansetron (ondansetron hydrochloride) - tablet - 8mg - ondansetron (ondansetron hydrochloride) 8mg - 5-ht3 receptor antagonists

European Union - English - EMA (European Medicines Agency)

tesaro bio netherlands b.v. - rolapitant - vomiting; nausea; cancer - antiemetics and antinauseants, - prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.varuby is given as part of combination therapy.